Telix Pharmaceuticals (TLPPF) Finished Goods (2023 - 2024)
Telix Pharmaceuticals' (TLPPF) quarterly Finished Goods came in at $9.2 million in Q4 2024, up 286.24% year-over-year from $2.4 million in Q1 2024, and up 286.24% quarter-over-quarter from $2.4 million in Q4 2023.
Powered by 
Analysis
Telix Pharmaceuticals (TLPPF) Finished Goods (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLPPF) has reported Finished Goods for 2 consecutive years, with $9.2 million the latest figure, recorded in Q4 2024.
- On a quarterly basis, Finished Goods rose 286.24% year-over-year to $9.2 million in Q4 2024; TTM through Dec 2024 was $9.2 million, a 286.24% increase from a year earlier, with the FY2024 full-year figure at $9.2 million, up 286.24% from the prior year.
- Finished Goods was $9.2 million for Q4 2024 at Telix Pharmaceuticals, up from $2.4 million in the prior quarter.
- Over five years, Finished Goods peaked at $9.2 million in Q4 2024 and troughed at $2.4 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.49 Bn | 198.50 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.93 Bn | 177.75 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.39 Bn | 124.53 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.17 Bn | 74.18 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.05 Bn | 55.87 Bn | 1.37 Bn |
| 6 | Moderna | 55.19 Bn | 50.05 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.99 Bn | 30.68 Bn | 992.69 Mn |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.91 Bn | 29.91 Bn | 1.16 Mn |
| 10 | Telix Pharmaceuticals | 3.72 Bn | 3.43 Bn | - |